Since its US Food and Drug Administration approval on March 14, 2024, resmetirom (Rezdiffra) has become a staple in MASH care for many patients. But how does its use in clinical practice compare to what was observed in the trials supporting its approval?
In this interview with HCPLive, Naim Alkhouri, MD, chief medical officer, chief of transplant hepatology, and director of the Fatty Liver Program at Arizona Liver Health, reviews findings from data for the first 72 patients prescribed resmetirom at 2 tertiary care centers in the US.
“What we are showing here is that in the real world, we are able to identify appropriate patients to be prescribed resmetirom based on noninvasive testing without the need for liver biopsy, and that the patient characteristics and the NIT data are very consistent with MAESTRO-NASH, implicating that we can really replicate the results from the phase 3 program, hopefully, in the real world,” Alkhouri said. “This is the first glimpse. We continue to collect more data… Our goal is to demonstrate that resmetirom was equally as effective in the real world as in the phase 3 clinical trials. More to come on this, but we are very excited to share the first real-world data on the use of resmetirom in the United States.”
For more on Dr. Alkhouri’s research: [ Ссылка ]
#Hepatology #MASH #MASLD #LiverDisease
